An observational study in Large B-cell Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 30 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by The Lymphoma Academic Research Organisation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation — 2 open to participants now, 4 under way, none of them phase 3. Lymphoma, B-Cell · The Lymphoma Academic Research Organisation.
Among the 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.
889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.
Browse Lymphoma, B-Cell studies →2 of the 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation are open now, in 1 country. Recruiting first, the newest first:
The Lymphoma Academic Research Organisation · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 150 across 71 observational studies indexed under Lymphoma, B-Cell.
Median enrollment 64 across the 8 interventional studies, 185 across the 2 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Lymphoma Academic Research Organisation is the lead sponsor of 60 studies on the registry; 12 are open to participants now.
1 of the studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06271057The Lymphoma Academic Research OrganisationGolcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation [8, 15].
French patients enrolled in the EAP before 1st of November 2024 and treated with at least Obinutuzumab pretreatment and one infusion of Glofitamab for R/R DLBCL We expect to collect data from 200-250 patients from this population with a minimum of 6 months of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated in Expanded Access Program to Glofitamab
Drug: Glofitamab
Glofitamab received for DLBCL in Early Phase Access
Best Complete Response Rate (best CRR) during treatment, assessed by investigator according to Lugano 2014 criteria.
Time frame: 6 months
Complete metabolic response rate and overall response rate (ORR) by investigator assessment according to Lugano 2014 criteria
Time frame: 1 month, 2 months, 3 months, 6 months
Progression-free survival (PFS)
Time frame: 6 months
Event-Free Survival (EFS)
Time frame: 6 months
Overall survival (OS)
Time frame: 6 months
immune effector cell-associated neurotoxicity syndrome (ICANS) rate
Time frame: 6 months
≥ grade 2 Cytokine release syndrome (CRS) rate
Time frame: 6 months
intensive care unit (ICU) admission rate
Time frame: 6 months
rate and cause of rehospitalization due to an adverse event potentially related to Glofitamab,
Time frame: 6 months
number of significant medical events leading to hospitalization
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Mar 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Lymphoma Academic Research Organisation